Logo image of JSPR

JASPER THERAPEUTICS INC (JSPR) Stock Overview

NASDAQ:JSPR - US4718712023 - Common Stock

2.8 USD
-0.04 (-1.41%)
Last: 8/29/2025, 4:30:02 PM
2.8 USD
0 (0%)
After Hours: 8/29/2025, 4:30:02 PM

JSPR Key Statistics, Chart & Performance

Key Statistics
52 Week High26.05
52 Week Low2.27
Market Cap45.50M
Shares16.25M
Float16.06M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-6.01
PEN/A
Fwd PEN/A
Earnings (Next)11-05 2025-11-05/amc
IPO11-20 2019-11-20
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


JSPR short term performance overview.The bars show the price performance of JSPR in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40 -50

JSPR long term performance overview.The bars show the price performance of JSPR in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of JSPR is 2.8 USD. In the past month the price decreased by -2.78%. In the past year, price decreased by -87.16%.

JASPER THERAPEUTICS INC / JSPR Daily stock chart

JSPR Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.87 371.68B
AMGN AMGEN INC 13.19 154.89B
GILD GILEAD SCIENCES INC 14.6 140.17B
VRTX VERTEX PHARMACEUTICALS INC 23.08 100.25B
REGN REGENERON PHARMACEUTICALS 12.72 61.55B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.53B
ARGX ARGENX SE - ADR 76.83 43.59B
ONC BEONE MEDICINES LTD-ADR 6.16 36.38B
INSM INSMED INC N/A 28.77B
BNTX BIONTECH SE-ADR N/A 24.04B
NTRA NATERA INC N/A 23.09B
BIIB BIOGEN INC 8.26 19.38B

About JSPR

Company Profile

JSPR logo image Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. The company is headquartered in Redwood City, California and currently employs 64 full-time employees. The company went IPO on 2019-11-20. The firm is focused on developing therapeutics targeting mast cell driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). The company also has ongoing programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as Lower to Intermediate Risk Myelodysplastic Syndrome (LR-MDS), and stem cell transplant conditioning regimens. The firm's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. The SCF/c-Kit pathway is a survival signal for mast cells. The company is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.

Company Info

JASPER THERAPEUTICS INC

2200 Bridge Pkwy Suite #102

Redwood City CALIFORNIA US

CEO: Bala Venkataraman

Employees: 64

JSPR Company Website

JSPR Investor Relations

Phone: 16505491400

JASPER THERAPEUTICS INC / JSPR FAQ

What is the stock price of JASPER THERAPEUTICS INC today?

The current stock price of JSPR is 2.8 USD. The price decreased by -1.41% in the last trading session.


What is the ticker symbol for JASPER THERAPEUTICS INC stock?

The exchange symbol of JASPER THERAPEUTICS INC is JSPR and it is listed on the Nasdaq exchange.


On which exchange is JSPR stock listed?

JSPR stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for JASPER THERAPEUTICS INC stock?

16 analysts have analysed JSPR and the average price target is 15.45 USD. This implies a price increase of 451.64% is expected in the next year compared to the current price of 2.8. Check the JASPER THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is JASPER THERAPEUTICS INC worth?

JASPER THERAPEUTICS INC (JSPR) has a market capitalization of 45.50M USD. This makes JSPR a Nano Cap stock.


How many employees does JASPER THERAPEUTICS INC have?

JASPER THERAPEUTICS INC (JSPR) currently has 64 employees.


What are the support and resistance levels for JASPER THERAPEUTICS INC (JSPR) stock?

JASPER THERAPEUTICS INC (JSPR) has a resistance level at 2.86. Check the full technical report for a detailed analysis of JSPR support and resistance levels.


Should I buy JASPER THERAPEUTICS INC (JSPR) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does JASPER THERAPEUTICS INC (JSPR) stock pay dividends?

JSPR does not pay a dividend.


When does JASPER THERAPEUTICS INC (JSPR) report earnings?

JASPER THERAPEUTICS INC (JSPR) will report earnings on 2025-11-05, after the market close.


What is the Price/Earnings (PE) ratio of JASPER THERAPEUTICS INC (JSPR)?

JASPER THERAPEUTICS INC (JSPR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.01).


What is the Short Interest ratio of JASPER THERAPEUTICS INC (JSPR) stock?

The outstanding short interest for JASPER THERAPEUTICS INC (JSPR) is 8.02% of its float. Check the ownership tab for more information on the JSPR short interest.


JSPR Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

JSPR Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to JSPR. JSPR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

JSPR Financial Highlights

Over the last trailing twelve months JSPR reported a non-GAAP Earnings per Share(EPS) of -6.01. The EPS decreased by -17.84% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -136.78%
ROE -186.49%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-79.38%
Sales Q2Q%N/A
EPS 1Y (TTM)-17.84%
Revenue 1Y (TTM)N/A

JSPR Forecast & Estimates

16 analysts have analysed JSPR and the average price target is 15.45 USD. This implies a price increase of 451.64% is expected in the next year compared to the current price of 2.8.


Analysts
Analysts77.5
Price Target15.45 (451.79%)
EPS Next Y-4.91%
Revenue Next YearN/A

JSPR Ownership

Ownership
Inst Owners89.72%
Ins Owners1.27%
Short Float %8.02%
Short Ratio1.69